Columbus, OH

In this episode, hosts discuss the implications of Dexcom announcing availability of their Stelo sensor and the FDA clearance of the Omnipod 5 for type 2 diabetes. August 26, 2024 will be remembered as the start of a new era in glucose monitoring and management. A day beginning with Dexcom’s announcement of availability and pricing for the first OTC glucose sensor in the Dexcom Stelo and ending with the FDA’s announcement of clearance for the Omnipod 5 Automated Insulin Delivery System (AID) for adults with type 2 diabetes—the first AID to receive FDA clearance for type 1 and type 2 diabetes.

Diabetes Dialogue: Stelo OTC Availability and Omnipod 5 for Type 2 Diabetes

Medical News Today

New research has found that people taking sulfonylurea, a common drug used for diabetes management, appear to be increasingly desensitized to signs that they are experiencing a hypoglycemic episode.

Common diabetes drug may desensitize people to dangerous drop in blood sugar

Parade

Find out when tracking your blood sugar can be helpful.

'I'm an Endocrinologist, and These Are the Exact Glucose Numbers to Aim for If You Want to Prevent Diabetes'

Insulet (Nasdaq:PODD) announced today that the FDA cleared its Omnipod 5 automated insulin delivery for use by people with type 2 diabetes. Clearance makes Omnipod 5, the company’s latest-generation AID system, the first and only such system cleared for type 1 and type 2 diabetes. Its indication covers those ages 18 and older in the type 2 population, while the system has been cleared for ages two and up in the type 1 bracket since 2022.

FDA clears Insulet Omnipod 5 for people with type 2 diabetes

Everyday Health

Adults in a preliminary study who had prediabetes and were overweight or had obesity also lost between 15 and 23 percent of their body weight.

Zepbound and Mounjaro Might Completely Erase Your Diabetes Risk

Insulin pens have become a game-changer for people managing diabetes. These handy devices offer a convenient, precise way to administer insulin without the hassle of traditional syringes. But what makes them so special? Insulin pens combine ease of use with accuracy, ensuring that users get the right dose every time. They come in various types, including disposable and reusable options, catering to different needs and preferences. With features like dose memory and fine-tuned dosing increments, insulin pens simplify diabetes management. Whether you're new to diabetes care or a seasoned pro, understanding the benefits and functionalities of these pens can make a significant difference in your daily routine.

24 Facts About Insulin Pens

Writers represent independent, third-party users who have joined our contributor program and self-verified their accounts. Writers are expected, like all users, to adhere to our Community Standards.

writer

Shin

Statins are widely recognized for their role in lowering low-density lipoprotein (LDL) cholesterol and reducing the risk of heart disease. But new research from the Cholesterol Treatment Trialists’ Collaboration (CTSU) has revealed that these life-saving medications may come with a small but significant drawback—an increased risk of developing diabetes, particularly in individuals already predisposed to the condition.

Statins and Diabetes: New Comprehensive Research Confirms Elevated Risk

While you're likely familiar with type 1 and type 2 diabetes, you've probably heard less about type 1.5 diabetes. Also known as latent autoimmune diabetes in adults (LADA), type 1.5 diabetes has features of both type 1 and type 2 diabetes. More people became aware of this condition after Lance...

Some People With Diabetes Could Unknowingly Have Type 1.5

Ozempic and Wegovy may have some new competition. Eli Lilly has announced that its new diabetes drug, Zepbound (tirzepatide), reduced the risk of developing Type 2 diabetes by 94% in prediabetic adults in a clinical trial. Additionally, treatment with tirzepatide resulted in sustained weight loss through the treatment period, with...

Eli Lilly says its new diabetes drug was 94% effective in clinical trials

Diabetic retinopathy (DR) usually takes several years to develop. In many cases, it may take at least 5 years for the condition to develop after a diagnosis of diabetes. However, the onset, progression, and extent of vision loss can vary widely. The risk of DR can. the longer a person...

How quickly can diabetic retinopathy develop?

Linearity FD Special Diabetes (K899M-5) is intended to simulate human patient samples for use in determining linearity, calibration verification, and the verification of reportable range for the following analyte: C-peptide and Insulin. Package Size: 5 x 2 mL. Open vial stability: 5 days when stored at 2-8°C. Easy-to-use analyzer...

Product Focus - Diabetes

Verywell Health

Eli Lilly shared more good news this week about the health benefits of tirzepatide—the active ingredient in the obesity and diabetes medications Zepbound and Mounjaro. Early results from a three-year clinical study indicate that the blockbuster GLP-1 medication can not only treat type 2 diabetes but may also prevent the condition in people with prediabetes and obesity or overweight. The clinical trial is the longest finalized study of tirzepatide so far.

Lilly's Tizepatide Cuts Type 2 Diabetes Risk by 94%, New Data Shows

There are tens of millions of people in the U.S. taking the cholesterol-lowering medications known as statins to prevent heart disease. This could be because the U.S. Preventative Services Task Force advises healthcare professionals to prescribe statins in patients ages 40 to 75 who have at least one risk factor for heart disease, such as diabetes or dyslipidemia, and an estimated 10-year cardiovascular risk of 10 percent or more.

Glaucoma joins growing list of statin side effects

If you are an adult living with kidney disease and excess weight or obesity, you may be eligible to join a trial studying the impact of tirzepatide on kidney function. Trial Name: Tirzepatide Study of Renal Function in People With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes: Focus on Kidney Hypoxia in Relation to Fatty Kidney Disease Using Multiparametric Magnetic Resonance Imaging (TREASURE-CKD)

New Trial Studying Tirzepatide for Chronic Kidney Disease

The FDA has cleared the Omnipod 5 for adults aged 18 years and older with type 2 diabetes. The automated insulin delivery system cut HbA1c by 0.8 percentage points at 13 weeks in the SECURE-T2D trial. The FDA has cleared an automated insulin delivery system for adults aged 18 years...

FDA clears tubeless automated insulin delivery system for adults with type 2 diabetes

Type 2 diabetes can now wear a device that will automatically deliver doses of insulin, following an expanded approval by the FDA on Monday. Called the Omnipod 5, it is the first to be approved for adults with type 2 diabetes and can be worn continuously for up to 3 days, working with a continuous glucose monitor.

Automated Insulin Device Now FDA-Approved for Type 2 Diabetes

Integrating gut microbiome-targeted therapies with conventional drugs to manage type 2 diabetes could be more effective, a new review suggests.

Gut microbiome plays a key role in managing type 2 diabetes

Hypoglycemia symptoms include having anxiety, emotional instability, dizziness, and lightheadedness. Here's a list with more signs to watch for.

10 Warning Signs of Low Blood Sugar

Pittsburgh, PA

Allegheny Health Network (AHN) implants innovative device to manage central sleep apnea in heart failure patients, reducing mortality rise and improving quality of life. Teams from the AHN Sleep Medicine Center and the AHN Cardiovascular Institute implanted remedē®, a pacemaker-like device that works to restore restful sleep for adult patients living with CSA. It stimulates normal breathing rhythms with small electrical currents to the diaphragm and can mitigate the need for continuous positive airway pressure (CPAP) systems and the masks that come with them.

AHN implants innovative device to manage central sleep apnea in heart failure patients

Insulet received U.S. clearance Monday for its Omnipod 5 system for Type 2 diabetes management — a first for the industry — making automated insulin delivery to control blood sugar available to millions of additional people living with diabetes. The system’s tubeless pump automatically adjusts insulin levels based...

Insulet’s Trang Ly on overcoming ‘clinical inertia’ in diabetes care

NewsBreak

Diabetes Dialogue: Sotagliflozin for T1D and Other ADCES 2024 Highlights

This episode focuses on sotagliflozin in type 1 diabetes and other highlights from the ADCES 2024 annual meeting. This episode of Diabetes Dialogue: Technology, Therapeutics, &...

Diabetes Dialogue: Sotagliflozin for T1D and Other ADCES 2024 Highlights

Comments / 0